Phase 2/3 Outsourced Spend By Provider Type
Source: Life Science Leader
By Industry Standard Research
ISR asked respondents responsible for outsourcing Phase 2/3 drug development how they allocate their outsourcing budget toward CROs of various sizes and academic medical centers. As expected, large, full-service CROs received the largest amount, accounting for 57% of outsourced spend overall. In a separate question, respondents were asked to select benefits of each provider type. Respondents selected an average of eight associated benefits for large CROs, about six for midsize and small CROs, and about four for academic medical centers.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more